BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Therapeutics to Present at Upcoming November Investor Conferences

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.Company update

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November.

Related news

CTMXCytomX Therapeutics, Inc.2026-10-29 12:00 EST

CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026

CTMXCytomX Therapeutics, Inc.2026-11-05 21:15 EST

CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

ERASErasca2026-11-03 13:00 EST

Erasca to Present at Upcoming Conferences in November

CMPXCompass Therapeutics2026-11-02 14:00 EST

Compass Therapeutics to Participate in Upcoming November Investor Events

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

MGNXMacroGenics2026-11-05 21:05 EST

MacroGenics to Participate in Upcoming Investor Conferences

STROSutro Biopharma2026-11-04 13:00 EST

Sutro Biopharma to Participate in Upcoming Investor Conferences

SNDXSyndax Pharmaceuticals2026-10-30 11:00 EST

Syndax Announces Participation in November Investor Conferences

View all latest news

CytomX Therapeutics, Inc.

Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates. Varsetatug Masetecan Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY...

Recent company news

CTMXCytomX Therapeutics, Inc.2026-11-05 21:15 EST

CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-11-02 13:00 EST

CytomX Therapeutics to Present at Upcoming November Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-10-29 12:00 EST

CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026

CTMXCytomX Therapeutics, Inc.2026-09-01 12:00 EST

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-08-27 12:00 EST

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

Stock data

Close
2.14 USD
Market cap
687.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States